Jazz Pharmaceuticals Plc Stock

$106.90

0.57% yesterday

Nasdaq, Jun 27, 10:13 pm CET

ISIN

IE00B4Q5ZN47

Symbol

JAZZ

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P MidCap 400

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Jazz Pharmaceuticals Plc Stock price

$106.90

-2.68 2.45% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.61 0.57%

ISIN

IE00B4Q5ZN47

Symbol

JAZZ

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P MidCap 400

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$6.5b

Enterprise Value

$9.3b

Net debt

$2.8b

Cash

$2.6b

Shares outstanding

61.6m

Valuation (TTM | estimate)

P/E

13.53 | 21.20

P/S

1.59 | 1.50

EV/Sales

2.28 | 2.15

EV/FCF

6.22

P/B

1.58

Financial Health

Equity Ratio

34.08%

Return on Equity

13.68%

ROCE

5.77%

ROIC

9.15%

Debt/Equity

1.29

Financials (TTM | estimate)

Revenue

$4.1b | $4.3b

EBITDA

$1.2b | $774.3m

EBIT

$594.5m

Net Income

$482.2m | $310.7m

Free Cash Flow

$1.5b

Growth (TTM | estimate)

Revenue

5.76% | 6.05%

EBITDA

2.72% | -42.81%

EBIT

3.58%

Net Income

45.79% | -44.54%

Free Cash Flow

51.34%

Margin (TTM | estimate)

Gross

88.81%

EBITDA

30.03% | 17.94%

EBIT

14.63%

Net

11.86% | 7.20%

Free Cash Flow

36.62%

EPS

$7.90

FCF per Share

$24.15

Short interest

11.14%

Employees

2.80k

Rev per Employee

$1.45m

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Jazz Pharmaceuticals Plc Stock Analysis

Unlock Scores for Free

??

24 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

21x Buy

88%

More details on Analyst Estimates Including Price Targets

24 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from Jazz Pharmaceuticals Plc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	4,065 4,065	6% 6% 100%
- Direct Costs	455 455	13% 13% 11%
Gross Profit	3,610 3,610	5% 5% 89%
- Selling and Administrative Expenses	1,548 1,548	13% 13% 38%
- Research and Development Expense	842 842	5% 5% 21%
EBITDA	1,221 1,221	3% 3% 30%
- Depreciation and Amortization	626 626	2% 2% 15%
EBIT (Operating Income) EBIT	595 595	4% 4% 15%
Net Profit	482 482	46% 46% 12%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Jazz Pharmaceuticals Plc Stock News

Neutral

PRNewsWire

●

18 days ago

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ES-SCLC first-line maintenance setting Jazz to host investor webcast on Tuesday, June 10 at 4:30 p.m. EDT / 9:30 p.m.

Neutral

PRNewsWire

●

18 days ago

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium oxybate Novel intermediate analysis from the DUET trial cohort of patients taking >9 grams evaluated safety and changes in daytime sleepiness in adults with narcolepsy taking Xywav dosages of 9-12 grams per night For U.S. media ...

Neutral

PRNewsWire

●

26 days ago

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance R...

More Jazz Pharmaceuticals Plc News

Company Profile

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Head office	Ireland
CEO	Bruce Cozadd
Employees	2,800
Founded	2005
Website	www.jazzpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now